EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum IL-33 Concentrations and the IL-12/IFN-? Axis According to Therapeutic Strategy in Rheumatoid Arthritis

Jasmina Jocic, Radiša Pavlovic, Ivan Jovanovic, Bojana Stamenkovic, Nikola Jocic, Sanja Stojanovic, Aleksandra Tomic Lucic, Sladana Pavlovic

Medical Principles and Practice · 09.11.2026

DOI: 10.1159/mpp/adpag041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Principles and Practice, online erschienen am 09.11.2026. Verfasst von Jasmina Jocic und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Interleukin-33 (IL-33) is involved in inflammatory pathways relevant to rheumatoid arthritis (RA) and may interact with the IL-12/interferon-gamma (IFN-γ) axis. However, the relationship between circulating IL-33 concentrations and different therapeutic strategies remains incompletely understood. Subjects and Methods: In this prospective observational study with cross-sectional analysis, 189 consecutive RA patients were stratified according to treatment: methotrexate (MTX), MTX plus TNF inhibitors (MTX+TNFi), tocilizumab (TCZ), and DMARD-naïve patients. Serum IL-33 concentrations were measured by ELISA. Disease activity indices (DAS28-ESR, CDAI, SDAI), inflammatory markers, and serum IL-12 and IFN-γ levels were assessed.

Results

IL-33 concentrations differed across therapeutic groups, with the highest levels observed in DMARD-naïve patients and lower levels in those receiving biologic therapy, particularly TCZ. IL-33 was associated with disease activity parameters and showed a modest positive correlation with IL-12. IFN-γ concentrations also differed among treatment groups, with the lowest levels observed in TCZ-treated patients.

Conclusions

Serum IL-33 concentrations varied across therapeutic groups in rheumatoid arthritis and were associated with selected indicators of inflammatory activity. Further studies are needed to clarify the role of IL-33 in the immunopathology of rheumatoid arthritis.

Zitieren

APA

Jocic, J., Pavlovic, R., Jovanovic, I., Stamenkovic, B., Jocic, N., Stojanovic, S., Tomic Lucic, A., & Pavlovic, S. (2026). Serum IL-33 Concentrations and the IL-12/IFN-? Axis According to Therapeutic Strategy in Rheumatoid Arthritis. Medical Principles and Practice. https://doi.org/10.1159/mpp/adpag041

Vancouver

Jocic J, Pavlovic R, Jovanovic I, Stamenkovic B, Jocic N, Stojanovic S, et al. Serum IL-33 Concentrations and the IL-12/IFN-? Axis According to Therapeutic Strategy in Rheumatoid Arthritis. Medical Principles and Practice. 2026. doi:10.1159/mpp/adpag041

BibTeX
@article{Jocic2026,
  author = {Jocic, Jasmina and Pavlovic, Radiša and Jovanovic, Ivan and Stamenkovic, Bojana and Jocic, Nikola and Stojanovic, Sanja and Tomic Lucic, Aleksandra and Pavlovic, Sladana},
  title = {Serum IL-33 Concentrations and the IL-12/IFN-? Axis According to Therapeutic Strategy in Rheumatoid Arthritis},
  journal = {Medical Principles and Practice},
  year = {2026},
  doi = {10.1159/mpp/adpag041}
}
Kostenlos starten →